Previous 10 | Next 10 |
The following slide deck was published by AzurRx BioPharma, Inc. in conjunction with this Read more ...
Thinly traded nano cap AzurRx BioPharma (NASDAQ: AZRX ) is up 20% premarket on increased volume on the heels of positive results from a Phase 2 clinical tria l evaluating lead drug MS1819-SD in chronic pancreatitis patients with exocrine pancreatic insufficiency. The data are ...
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that a present...
Noteworthy events during the week of March 17 - 23 for healthcare investors. More news on: SCYNEXIS, Inc., Sage Therapeutics, Inc., Intrexon Corporation, Healthcare stocks news, , Read more ...
BROOKLYN, N.Y., March 15, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company wil...
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced a poster prese...
Dosing is underway in a Phase 2 clinical trial, OPTION , evaluating AzurRx BioPharma's ( AZRX +30% ) MS1819-SD in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency , a deficiency in pancreatic enzymes that prevents normal food digestion. More news on: AzurRX Biopha...
Gainers: Kandi Technologies Group (NASDAQ: KNDI ) +47% . LeMaitre Vascular (NASDAQ: LMAT ) +28% . AzurRx BioPharma (NASDAQ: AZRX ) +29% . Blink Charging (NASDAQ: BLNK ) +21% . Carrols Restaurant Group (NASDAQ: TAST ) +17% . OneSpan (NASDAQ: OSPN ) +17% . Garmin (NASDAQ: GRMN ) ...
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, this morning issued a clinical development and strategic corporate update. In the update, the company reports that the first patients have been dosed...
First patients dosed in open-label, cross-over Phase II OPTION study with MS1819-SD for exocrine pancreatic insufficiency in cystic fibrosis. Five clinical trial sites in the U.S. activated for OPTION study Additional European sites now expected with Ministry of Health approval ...
News, Short Squeeze, Breakout and More Instantly...
AzurRx BioPharma Inc. Company Name:
AZRX Stock Symbol:
NASDAQ Market:
AzurRx BioPharma Inc. Website:
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (G...
Why Investors Are Watching These 3 Penny Stocks Right Now There are plenty of ways to find the best penny stocks to buy right now. And, one method that many penny stocks investors use is looking at what top investors are buying alongside other metrics. While this can be a good strat...
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroint...